

Diego Bagnasco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4148993/publications.pdf>

Version: 2024-02-01

74
papers

1,736
citations

279487

23
h-index

301761

39
g-index

74
all docs

74
docs citations

74
times ranked

2326
citing authors

#	ARTICLE	IF	CITATIONS
1	A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. <i>International Archives of Allergy and Immunology</i> , 2016, 170, 122-131.	0.9	164
2	Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 186-200.	1.1	152
3	Type 2 immunity in asthma. <i>World Allergy Organization Journal</i> , 2018, 11, 13.	1.6	116
4	Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. <i>World Allergy Organization Journal</i> , 2019, 12, 100007.	1.6	82
5	Minimal clinically important difference for asthma endpoints: an expert consensus report. <i>European Respiratory Review</i> , 2020, 29, 190137.	3.0	72
6	Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. <i>Frontiers in Medicine</i> , 2017, 4, 135.	1.2	65
7	IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 95-100.	1.1	59
8	One year of mepolizumab. Efficacy and safety in real-life in Italy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101836.	1.1	57
9	<p>>A case of chronic eosinophilic pneumonia in a patient treated with dupilumab</p>>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 869-875.	0.9	49
10	Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. <i>Respiratory Medicine</i> , 2021, 176, 106261.	1.3	44
11	Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	42
12	30 years of sublingual immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1107-1120.	2.7	41
13	Personalized Medicine in Allergy. <i>Allergy, Asthma and Immunology Research</i> , 2017, 9, 15.	1.1	40
14	Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?. <i>Frontiers in Immunology</i> , 2017, 8, 242.	2.2	37
15	The North-Western Italian experience with anti IL-5 therapy and comparison with regulatory trials. <i>World Allergy Organization Journal</i> , 2018, 11, 34.	1.6	36
16	Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2539-2541.	2.7	36
17	COVID-19 in severe asthmatic patients during ongoing treatment with biologics targeting type 2 inflammation: Results from a multicenter Italian survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 871-874.	2.7	33
18	Oral Corticosteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	1.6	30

#	ARTICLE	IF	CITATIONS
19	Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 88.	2.4	29
20	Strategies to reduce corticosteroid-related adverse events in asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 61-67.	1.1	28
21	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. <i>Respiratory Medicine</i> , 2020, 171, 106080.	1.3	28
22	Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 29-38.	1.0	27
23	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 40-45.	1.0	27
24	Targeting Interleukin-5 or Interleukin-5R α : Safety Considerations. <i>Drug Safety</i> , 2017, 40, 559-570.	1.4	22
25	Current insights in allergen immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 152-154.	0.5	20
26	Real-life studies of biologics used in asthma patients: key differences and similarities to trials. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 951-958.	1.3	20
27	Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?. <i>Drugs in Context</i> , 2019, 8, 1-11.	1.0	20
28	Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 1019-1026.	1.0	18
29	Severe asthma: One disease and multiple definitions. <i>World Allergy Organization Journal</i> , 2021, 14, 100606.	1.6	18
30	Quick Olfactory Sniffinâ€™ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients. <i>World Allergy Organization Journal</i> , 2021, 14, 100497.	1.6	17
31	ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. <i>World Allergy Organization Journal</i> , 2021, 14, 100592.	1.6	17
32	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1460-1463.	2.7	16
33	Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 64, 101966.	1.1	16
34	Update on immunotherapy for the treatment of asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 18-24.	1.2	15
35	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 54, 87-89.	1.1	15
36	<p></p>Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 301-313.	1.5	15

#	ARTICLE	IF	CITATIONS
37	Biological agents for severe asthma: the evolution of the at-home self-injection approach. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 421-427.	1.1	15
38	Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 113-120.	1.5	14
39	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , 2021, 14, 100509.	1.6	14
40	Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases. <i>Journal of Thoracic Disease</i> , 2016, 8, E716-E725.	0.6	12
41	Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 601-606.	1.4	12
42	Biosimilars in allergic diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 68-73.	1.1	11
43	The path to personalized medicine in asthma. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 957-965.	1.0	10
44	Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1087-1094.	1.0	9
45	Biologics for the Treatments of Allergic Conditions. <i>Immunology and Allergy Clinics of North America</i> , 2020, 40, 549-564.	0.7	9
46	The safety of monoclonal antibodies in asthma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1087-1095.	1.0	8
47	<p>New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic</p>. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 89-95.	3.0	8
48	Biologics for severe asthma: what we can learn from real-life experiences?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 64-70.	1.1	8
49	Personalized medicine and allergen immunotherapy: the beginning of a new era?. <i>Clinical and Molecular Allergy</i> , 2021, 19, 10.	0.8	8
50	Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center. <i>Biomedicines</i> , 2022, 10, 200.	1.4	8
51	Umeclidinium for the treatment of uncontrolled asthma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 761-766.	1.9	7
52	Evolving phenotypes to endotypes: is precision medicine achievable in asthma?. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 163-172.	1.0	7
53	Real-life studies in allergen immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 361-367.	1.1	7
54	Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports. <i>Clinical and Translational Allergy</i> , 2021, 11, e12067.	1.4	7

#	ARTICLE	IF	CITATIONS
55	Specific Therapy for T2 Asthma. <i>Journal of Personalized Medicine</i> , 2022, 12, 593.	1.1	7
56	Severe asthma, biologics, and auto-injection: Yes, no, may be!. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 444-445.	2.7	6
57	Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101874.	1.1	5
58	Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study. <i>BioMed Research International</i> , 2020, 2020, 1-4.	0.9	5
59	Do the current guidelines for asthma pharmacotherapy encourage over-treatment?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1283-1286.	0.9	4
60	Personalizing the approach to asthma treatment. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 299-304.	0.4	3
61	When to stop biologics. Severe asthma exacerbation after mepolizumab discontinuation. <i>European Annals of Allergy and Clinical Immunology</i> , 2019, 51, 135.	0.4	3
62	Application of bioendoscopy filters in endoscopic assessment of sinonasal Schneiderian papillomas. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1025-1028.	1.5	2
63	MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1435-1441.	1.4	1
64	Importance of inhaler device use status in the control of asthma and COPD: a real life study.. , 2018, , .		1
65	Severe asthma: one disease many definitions. , 2019, , .		1
66	New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases. <i>Current Pharmaceutical Biotechnology</i> , 2017, 18, 378-383.	0.9	1
67	Multiple Pulmonary Nodules and Unexplained Fever: When the Pulmonologist Fails. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 309-311.	1.0	0
68	Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy. <i>World Allergy Organization Journal</i> , 2019, 12, 100086.	1.6	0
69	Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: from eligibility criteria to real practice. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB17.	1.5	0
70	Overlapping biological drugs prescription status: real life in Genoa. , 2018, , .		0
71	A phone call shortens waiting list. Interventions to reduce waiting lists and improve the performance of a pneumological clinic. , 2019, , .		0
72	One year of mepolizumab in severe asthma in Italy: efficacy and safety. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	Switch Omalizumab â€“ Mepolizumab: real life experience. , 2019, , .		0
74	Cerebrospinal Fluid Leak Repair: Usefulness of Intrathecal Fluorescein for Correct Topographic Identification of the Skull Base Defects. World Neurosurgery, 2022, 160, e267-e277.	0.7	0